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Available online 6 July 2012Introduction. Juvenile idiopathic arthritis (JIA) comprises a poorly understood group of
chronic autoimmune diseases with variable clinical outcomes. We investigated whether
the synovial fluid (SF) proteome could distinguish a subset of patients in whom disease
extends to affect a large number of joints.
Methods. SF samples from 57 patients were obtained around time of initial diagnosis of JIA,
labeled with Cy dyes and separated by two-dimensional electrophoresis. Multivariate
analyses were used to isolate a panel of proteins which distinguish patient subgroups.
Proteins were identified using MALDI-TOF mass spectrometry with expression verified by
immunochemical methods. Protein glycosylation status was confirmed by hydrophilic
interaction liquid chromatography.
Results. A truncated isoform of vitamin D binding protein (VDBP) is present at significantly
reduced levels in the SF of oligoarticular patients at risk of disease extension, relative to
other subgroups (p<0.05). Furthermore, sialylated forms of immunopurified synovial VDBP
were significantly reduced in extended oligoarticular patients (p<0.005).
Conclusion. Reduced conversion of VDBP to a macrophage activation factor may be used to
stratify patients to determine risk of disease extension in JIA patients.
Crown Copyright © 2012 Published by Elsevier B.V. Open access under CC BY license.Keywords:
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Inflammation1. Introduction
About one in every thousand children in the UK suffers from
juvenile idiopathic arthritis (JIA) [1]. JIA is a heterogeneous
group of inflammatory disorders affecting the musculoskeletalelfast, Centre for Infection an
vid.gibson@ucdenver.edu
d by Elsevier B.V. Open accesystem. Of the seven subsets of JIA identified according to ILAR
classification [2], oligoarticular, extended oligoarticular, and
polyarticular are the commonest. Adverse outcomes canpresent
to varying degrees regardless of disease subtype [3]. In approxi-
mately 25% of children with oligoarticular JIA, over time thed Immunity, Health Sciences Building, 97 Lisburn Road, Belfast, BT9 7BL,
(D.S. Gibson).
ss under CC BY license.
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extendedoligoarticulardisease [4].Clinical, laboratoryor radiologic
parameters cannot accurately predict disease extension. Ex-
tended oligoarticular JIA is much more difficult to treat due to
its characteristic resistance to second‐line therapies [5]. It
is therefore important to define more sensitive markers to
determine the risk of inflammation spreading to previously
unaffected joints. If it was possible to identify these children
earlier, more effective therapies could be instigated to prevent
joint and periarticular damage.
Previous studies have suggested that measurement of a
selected set of synovial fluid or plasma proteins may be used
to discriminate clinically and biologically relevant JIA sub-
groups [6–9]. A recent study reported a significant reduction in
the ratio of CD4:CD8 positive T cells with a corresponding
increase in the levels of CCL5 in the synovial fluid of extended
oligoarticular patients [10].
Post‐translational modifications of proteins are frequently
overlooked as candidates are identified in biomarker discovery
studies. However, covalent modifications of proteins by oxida-
tion, phosphorylation or glycosylation can have profound effects
on protein transport, function, stability and recognition. Growing
evidence suggests a significant role for glycosylation in a range of
arthritic and autoimmune disorders [11,12]. Specifically, protein
glycosylation motifs affect a wide variety of innate and adaptive
immunological processes including inflammation, cellular infil-
tration, cell communication and adhesion, and lymphocyte
tolerance [13–17]. Changes in the glycosylation of proteins such
as acute-phase proteins and antibodies have already been
recorded in the synovial fluid and plasma of arthritis patients,
but no relationship to clinical subtype or outcome has yet been
established in JIA [18–22].
This study is focused on identifying protein isoforms in a
de novo cohort of children with newly diagnosed JIA that will
predict disease spread. The synovial fluid proteome of the
persistent oligoarticular patient subgroupwas compared to thatTable 1 – Patient demographics and laboratory characteristics.
Characteristic
Oligoarticular Extended-to-be olig
(n=26) (n=8)
Sex, no. (females) 21 7
Age at time of biopsy (year) 5.6 (4.4) 6.1 (4.5)
Disease duration (months) 6.2 (4.3) 7.4 (7.5)
Swollen joint count 2.3 (1.2) 3.0 (0.9)
Neutrophils (×108 cells/L) 4.7 (2.4) 5.9 (1.7)
Lymphocytes (×108 cells/L) 3.7 (1.7) 4.5 (2.1)
Monocytes (×108 cells/L) 0.8 (0.3) 1.0 (0.3)
ESR (mm/h) 16.3 (15.0) 36.5 (32.7)
C reactive protein (mg/L) 8.5 (14.5) 11.4 (7.8)
Rheumatoid factor status
+ve 0 0
−ve 26 8
Antinuclear antibody status
+ve 12 5
−ve 14 3
Clinical and demographic characteristics of the study subjects at prese
subjects. CRP = C-reactive protein and ESR = erythrocyte sedimentation rof patients who show a spread after the first 6 months post
diagnosis to involve five or more joints i.e., the extended-to-be
oligoarticular subgroup. Novel mass spectrometry based anal-
yses were employed to resolve protein post-translational
modificationswhich are not apparent by conventional antibody
based methods.2. Materials and methods
2.1. Patients
Fifty-seven patients with newly diagnosed untreated JIA
according to International League Against Rheumatism
criteria entered this study and were followed for 1 year. At
the time of initial sampling there were 34 children with
oligoarticular arthritis, 18 with polyarticular arthritis (16
rheumatoid factor negative) and 5 with psoriatic or enthesitis
related arthritis. Patient data shown in Table 1 refers to clinical
findings at the time of joint aspiration and biopsy i.e. at initial
presentation before disease extension. Disease extension was
defined as 5 or more joints involved after 6 months from
disease commencement. At 1 year, 8 oligoarticular cases had
been reclassified as having extended oligoarticular JIA.
Patients were examined by a consultant rheumatologist
(M.E.R.) who confirmed their diagnosis. For the purposes of
this study, only initial synovial fluids from children with
disease duration of less than 1 year and steroid and
DMARD naive were included. Arthrocentesis and subsequent
joint steroid injection were performed according to clinical
need.
Clinical details recorded included subtype of JIA, age, sex,
disease duration, erythrocyte sedimentation rate (ESR) and
C-reactive protein (CRP). Treatments applied after samples
were drawn are also listed. Local inflammation was defined as
both joint swelling and pain on physical examination. All SFsSubtype Total
oarticular Polyarticular Psoraitic/enthesitis
(n=18) (n=5) (n=57)
15 2 45
9.9 (5.0) 12.8 (3.1) 7.7 (5.1)
7.4 (7.2) 9.0 (7.9) 7.0 (6.0)
10.9 (9.4) – 4.5 (5.5)
5.4 (1.8) 6.7 (1.4) 5.3 (2.1)
3.0 (1.7) 2.4 (1.1) 3.5 (1.8)
0.8 (0.4) 0.7 (0.3) 0.8 (0.4)
38.6 (35.0) 48.0 (22.8) 29.8 (28.4)
30.9 (43.2) 44.0 (44.2) 20.1 (32.2)
2 0 2
16 5 55
9 1 27
9 4 30
ntation. Values are the mean±standard deviation or the number of
ate.
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at the samevisit. Sampleswere immediately centrifuged (5000 g,
15 min, 4 °C), aliquoted and stored (−80 °C) for at least 1 year to
allow for clinical reclassification. Medical Ethics Committee
approval was obtained for this study at Green Park Healthcare
Trust and patient assent and parent informed consent given
(ORECNI 408/03).
2.2. Sample preparation
Samples were dialyzed (overnight, 4 °C, distilled water) to
remove salts using a 3.5 kDa cutoff Slide-A-Lyzer cassette
(Pierce Biotechnology, Inc., Rockford, IL). Each sample was
snap frozen in liquid nitrogen and lyophilized overnight on a
freeze-dryer (MartinChrist GmbH,Osterode amHarz, Germany).
Samples were rehydrated in sample rehydration buffer (8 M
Urea, 2% CHAPS and 0.002% bromophenol blue; Invitrogen Ltd.,
Paisley, UK). Protein concentrations were measured using the
PlusOne 2-D Quant kit according to the manufacturer's guide-
lines (GE Healthcare, Bucks, UK).
2.3. Difference in-gel electrophoresis (DIGE)
DIGE was performed at room temperature with Ettan IEF and
vertical gel systems and associated power supply, strips, gels
and reagents according to the manufacturer's guidelines (GE
Healthcare, Bucks, UK) as described before [9,22]. Each
synovial fluid and plasma sample was minimally labeled
with Cy5 and Cy3 fluorescent dyes and an internal pooled
standard (Cy2) sample was included according to the
manufacturer's recommendations. 50 μg of each Cy5 and
Cy3 labeled sample and Cy2 labeled standard was combined
and resuspended in an equal volume of sample buffer (8 M
Urea, 130 mM DTT, 4% (w/v) CHAPS, 2% (v/v) Pharmalyte 4–7).
24 cm Immobiline DryStrip pH 4–7 linear immobilized pH
gradient (IPG) strips were rehydrated overnight with the
relevant sample mixes. First-dimension separation of pro-
teins by isoelectric focusing (IEF) was performed for a total of
75,000 Vh (2 mA/5 W limit per strip) including a final 8000 V
step for 1 h to obtain improved resolution. After IEF, the strips
were equilibrated first in 1% (w/v) dithiothreitol and then 2.5%
(w/v) iodoacetamide. IPG strips were each laid into single well
12% PAGE gels and sealed in place with 1% agarose (w/v) in
running buffer (25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS
and bromophenol blue). The second dimension separation
was undertaken at 0.75 W/gel for 19 h. A preparative gel
loaded with 500 μg of unlabeled sample was silver-stained
withmass spectrometry compatible reagents for spot excision
(Pierce Biotechnology, Inc., Rockford, IL, USA).
2.4. Image and cluster analysis
Pre-labeled proteins were visualized using a Typhoon 9410
imager (GE Healthcare, Bucks, UK). Gel image analysis was
performed with Progenesis Samespots software (version 2.0,
build 2644.18003; Nonlinear Dynamics Ltd., Newcastle upon
Tyne, UK). All gel images were aligned to a reference gel and
the same spot outlines were overlaid onto all images to
ensure no data were omitted. The normalized volume (NV) for
each spot on each gel was calculated from the Cy3 (or Cy5) toCy2 spot volume ratio. Log transformation of the spot
volumes was used to generate normally distributed data. Log
normalized volume (LNV) was used to compare spot abun-
dance. Differential spot analysis was performed on aggregate
‘master’ gels of the patient subgroups. Each comparison was
filtered to find spots (a) with a p-value <0.05 for the unpaired
t test and (b) having a greater than 1.5-fold change in average
LNV expression between the groups.
Expression data were analyzed using Epclust, a generic data
clustering, visualization, and analysis tool (http://www.bioinf.
ebc.ee/EP/EP/EPCLUST/). Hierarchical analysis reorderedprotein
expression patterns in an agglomerative fashion, using the
weighted pair-group average (WPGMA) clustering procedure.
Euclidean ranked correlation was the similarity measure used
to group or separate the expression data. A heat map was
produced accompanied by a dendrogramdepicting the extent of
similarity between the different groups in the samples.
2.5. Mass spectrometry identification and verification
Protein spots were excised from silver-stained 2DE gels and
digested according to the protocol described previously [8].
Briefly, the gel spots were washed, reduced and alkylated,
then dehydrated with acetonitrile. The proteins were digested
overnight with trypsin (Promega, Southhampton, UK; modi-
fied trypsin, 37 °C) and the resulting peptides concentrated on
a ZipTip micro purification column and eluted onto an anchor
chip target for analysis (4800 MALDI-TOF/TOF mass spec-
trometer; Applied Biosystems, Warrington, UK). Mass analysis
was performed in the positive ion reflector mode. Some of the
peptides from each digest were analyzed in MS/MS mode to
obtain partial peptide sequence data. Mass spectra were
acquired in the 800–4000 m/z scan range (Table 2). The mass
accuracy was calibrated to within 50 ppm using calibration
standards (a mix over 900–3700m/z from Applied Biosystems).
To identify proteins, MS data were used to query the
non-redundant and validated sequence database (Uni-Prot
2009.09.23; contained 522,019 entries) using Mascot (version
2.2.03).
Database search parameters were: (i) trypsin cleaves on the
C-terminal side of K and R residues unless the next residue is
P, (ii) no fixed modifications, (iii) carbamidomethyl (C) and
oxidation (M) variable modifications, (iv) up to 1 missed
cleavage permitted with no fixed modifications, (v) peptide
tolerance set at 100 ppm for the precursor ions, and (vi) a
0.25 Da mass tolerance for the fragment ions. The acceptance
criteria for PMF based identifications was a minimum Mascot
score of 50, using a 95% confidence interval threshold (p<0.05).
The peptide ions identified in this study by MALDI-TOF and
further validated by collision induced dissociation (CID) MS/MS
analysis were independently matched to single protein entries
in the database.
2.6. Immunohistochemistry and ELISA
Immunohistochemistry was performed on synovial membrane
biopsies to confirm tissue expression. Synovial membrane
tissues were obtained from each patient by needle biopsy,
coated in OCT compound, snap frozen in liquid nitrogen and
stored at −80 °C. Cryostat sections of 7 μm were cut (Leica CM
Table 2 –Mass spectrometry of differentially expressed proteins.
Cluster Spot
no.
Fold difference between subgroups (unpaired t-test
with p<0.05 highlighted)
Protein name UniProt
accession
Mascot
score
Total ion
score
Sequence
coverage (%)
Matched
peptides
Verification
CID ions
Oligo vs ext.
oligo
p Oligo vs
poly
p Ext. oligo
vs poly
p
A 428 −6.32 0.30 −6.23 0.30 −1.02 0.95 Complement factor B CFAB_HUMAN 69 62 4 4 1
529 −2.60 0.31 −4.69 0.19 1.80 0.30 Ig gamma-2 chain C
region
IGHG2_HUMAN 191 146 18 8 3
530 1.20 0.86 −8.52 0.14 10.20 0.33 Ig kappa chain C
region
IGKC_HUMAN 225 195 34 2 2
750 −7.37 0.14 −9.96 0.13 1.35 0.31 Haptoglobin HPT_HUMAN 244 212 16 7 6
861 −3.20 0.11 −1.82 0.35 −1.75 0.38 Haptoglobin HPT_HUMAN 368 289 28 12 7
1346 −1.98 0.31 −2.09 0.28 1.06 0.86 Apolipoprotein A-IV APOA4_HUMAN 108 50 27 11 2
B 228 −2.25 0.002 −1.95 0.02 −1.15 0.59 Alpha-1-antitrypsin A1AT_HUMAN 172 118 22 10 4
1302 −1.46 0.36 −2.65 0.05 1.82 0.15 Alpha-1-antitrypsin A1AT_HUMAN 223 189 17 8 3
1303 −1.49 0.42 −3.32 0.06 2.23 0.09 Alpha-1-antitrypsin A1AT_HUMAN 293 248 16 9 5
1375 −4.30 0.01 1.41 0.61 −6.07 0.14 Serum albumin ALBU_HUMAN 259 178 21 13 5
1376 −2.93 0.01 1.28 0.67 −3.74 0.15 Serum albumin ALBU_HUMAN 443 326 29 18 7
C 196 −1.61 0.08 −1.88 0.02 1.17 0.48 Transthyretin TTHY_HUMAN 493 417 72 8 4
1252 −2.25 0.01 −1.06 0.82 −2.12 0.01 Vitamin D-binding
protein
VTDB_HUMAN 283 222 21 11 5
1253 −1.86 0.01 1.20 0.40 −2.24 0.01 Vitamin D-binding
protein
VTDB_HUMAN 761 640 36 16 10
1265 −1.75 0.04 −1.53 0.12 −1.14 0.65 Haptoglobin HPT_HUMAN 599 515 25 12 7
D 652 −2.09 0.20 −2.01 0.22 −1.04 0.94 Haptoglobin HPT_HUMAN 137 101 9 4 3
781 −2.48 0.01 −2.54 0.01 1.03 0.93 Haptoglobin HPT_PONAB 166 146 14 5 2
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876 1.07 0.88 1.79 0.45 −1.67 0.51 Alpha-1B-glycoprotein A1BG_HUMAN 106 80 13 6 1
E 175 2.23 0.14 2.21 0.10 1.01 0.99 Serotransferrin TRFE_HUMAN 627 425 34 26 9
178 3.22 0.09 1.12 0.77 2.88 0.10 Serotransferrin TRFE_HUMAN 628 468 22 18 11
191 3.19 0.09 2.83 0.06 1.13 0.80 Serotransferrin TRFE_HUMAN 495 393 22 19 10
557 2.05 0.06 2.36 0.0003 −1.15 0.58 Serum albumin ALBU_HUMAN 210 165 15 10 3
1358 1.44 0.07 1.73 0.001 −1.21 0.32 Alpha-1-antitrypsin A1AT_HUMAN 211 159 24 10 4
1478 −1.12 0.66 1.42 0.15 −1.59 0.12 Apolipoprotein A-I APOA1_HUMAN 435 332 49 14 8
1483 −1.05 0.82 1.44 0.05 −1.51 0.05 Alpha-1-antitrypsin A1AT_HUMAN 706 554 49 18 6
1484 −1.08 0.74 1.40 0.14 −1.51 0.13 Serum albumin ALBU_HUMAN 474 410 18 13 5
F 1431 −1.04 0.91 1.77 0.11 −1.84 0.12 Vitamin D-binding
protein
VTDB_HUMAN 292 228 16 9 5
1435 1.09 0.73 1.68 0.06 −1.54 0.19 Vitamin D-binding
protein
VTDB_HUMAN 345 309 24 8 4
1437 1.30 0.31 1.62 0.03 −1.18 0.52 Transthyretin TTHY_HUMAN 84 70 9 2 2
1438 1.34 0.22 1.59 0.02 −1.25 0.39 Transthyretin TTHY_HUMAN 102 81 18 3 2
1457 1.51 0.07 1.36 0.11 1.11 0.66 Haptoglobin HPT_HUMAN 234 208 12 6 4
G 873 −8.25 0.05 −1.92 0.31 −4.30 0.03 Vitamin D-binding
protein
VTDB_HUMAN 365 295 23 12 5
875 −1.13 0.83 4.42 0.07 −5.01 0.06 Alpha-1-antitrypsin A1AT_HUMAN 286 235 16 8 5
905 2.44 0.12 1.78 0.21 1.38 0.49 Apolipoprotein A-II APOA2_HUMAN 61 17 21 3 3
906 1.56 0.56 1.75 0.28 −0.12 0.86 Haptoglobin HPT_HUMAN 56 42 6 2 1
1416 9.27 0.35 1.47 0.61 6.32 0.38 Apolipoprotein A-I APOA1_HUMAN 126 s 16 4 3
Protein name, mass spectrometry data, fold differences between subgroups and their statistical significance are compiled for 36 of identified synovial fluid proteins. Spot trypsin digests were identified
using matrix assisted laser desorption ionization (MALDI-TOF/TOF), correlated to compiled peptide data (Matrixscience). p-Values in bold highlight inter-subgroup comparisons which reached statistical
significance (p<0.05) by unpaired t test. Peptide ion sequence and peak lists can be found in a Supplement Table 1A–D. In a comparison between persistent oligoarticular patients and those who later
exhibit disease extension, 23 of these proteins differed by at least 1.5 fold (labeled in Fig. 1).
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5484 J O U R N A L O F P R O T E O M I C S 7 5 ( 2 0 1 2 ) 5 4 7 9 – 5 4 9 21900; Meyer Instruments, Inc.), acetone fixed, air-dried and then
rehydrated. Endogenous peroxidasewas blocked, sections rinsed
and probed with VDBP primary antibody, Factor VIII or isotype
matched antibody (negative control). Biotinylated Sambucus
nigra lectin was used to probe for sialic acid residues (Vector
laboratories Inc., Burlingame, CA, USA). Tissue sections were
incubated with the Envision+Dual link system sHRP (DAKO A/S,
Glostrup, Denmark) or streptavidin HRP polymer (Sigma-Aldrich
Inc., St. Louis, MO, USA). Again, sections were washed, stained
with DAB solution, rinsed and counterstained in Mayer's
hematoxylin. Sections were washed, dehydrated, and air-dried.
Sections were cover-slipped and imaged with an Olympus BX41
light microscope and JVC 3CCD camera (Olympus Ltd., Essex,
UK).
Enzyme-linked immunosorbant assays (ELISA) for C-reactive
protein (CRP) and VDBP (R&D Systems, Minneapolis, MN, USA)
were performed according to the manufacturer's guidelines on
both synovial fluid and plasma from the study cohort. ELISA
plateswere read on aMultiscanMCC/340 plate reader at 450 nm
(Thermo Labsystems, Helsinki, Finland).
2.7. Immunoprecipitation, desiaylation and mass
spectrometry analysis
VDBP polyclonal antibody (DAKOA/S, Glostrup, Denmark) was
immobilized on Direct IP© agarose beads (Thermo Pierce
Scientific, Rockford, IL, USA) to form the immune complex.
Synovial fluids from all study patients were incubated with
the immune complex overnight at 4 °C with end to end
mixing. The complex was washed according to the manufac-
turer instructions and bound VDBP was dissociated with a
minimal volume of low pH elution buffer. Immunopurified
VDBP samples were lyophilized and resolubilized in 0.1%
RapidGest SF (Waters Technologies Corporation, Millford, MA,
USA) in 50 mM NH4HCO3, reduced with dithiothreitol and
alkylated with iodoacetamide.
The linearized VDBP was then split for three separate
analyses: (i) one dimensional gel electrophoresis and (ii)
MALDI-TOF mass spectrometry, of the intact protein, and (iii)
enzymatic removal and mass spectrometry of sialic acid
residues. A Criterion gel tank and 4–20% TGX precast gel
were run according to manufacturer's guidelines (Biorad
Laboratories Inc., Hercules, CA, USA). A purified form of
human VDBP was run with IP samples as a positive control
(2 μg) (Athens Research & Technology Inc., Athens, GA, USA).
Once the gels were run, proteins were fixed (with 7% glacial
acetic acid, 30% methanol) and visualized with GelCode Blue
coomassie dye reagent (Thermo Pierce Scientific, Rockford, IL,
USA). Immunopurified samples of VDBP were resuspended in
80% acetonitrile, 0.1% trifluoroacetic acid and spotted in
duplicate onto a MALDI target plate with sinnapinnic acid
matrix. Intact proteins were analyzed using a Voyager
STR+MALDI-TOF mass spectrometer in linear mode (Applied
Biosystems Corporation, Carlsbad, CA, USA). A highmolecular
weight mixture was used for calibration (Bruker Daltronics
Inc., Billerica, MA, USA).
Equal quantities of denatured VDBP were treated with α2-3
neuraminidase (sialidase) overnight at 4 °C to remove sialic
acid residues (New England Biolabs Inc., Ipswich, MA, USA).
Released glycans were enriched and separated from proteinbyMassPREP™ hydrophilic interaction liquid chromatography
(HILIC) mElution plate (Waters Technologies Corporation,
Millford, MA, USA). Glycan samples were resuspended in
ethanol with 2,5-dihydroxybenzoic acid (DHB) matrix and
spotted in duplicate onto a MALDI target plate. Glycans were
analyzed in triplicate using a Voyager STR+MALDI-TOF mass
spectrometer in reflector mode. A low molecular weight
mixture was used for instrument calibration (Bruker Daltronics
Inc., Billerica, MA, USA). Progenesis MALDI software v1.4 was
used to normalize, remove noise and align MALDI-TOF spectra
and accurately assess ion masses (Nonlinear Dynamics Ltd,
Newcastle upon Tyne, UK). Peaks were normalized by total ion
current and normalized peak height was used as the statistics
measure.
2.8. Statistical analysis
Significant differences between DIGE normalized spot vol-
umes of the study subgroups were calculated using the
unpaired Student's t-test (within Progenesis Samespots soft-
ware); MALDI normalized peak height data was analyzed by
ANOVA (within Progenesis MALDI software). DIGE, MALDI and
ELISA data were analyzed using GraphPad Prism (version 5.03;
GraphPad Software Inc., La Jolla, CA, USA) to construct
receiver operator characteristic curves.3. Results
3.1. Synovial fluid proteome and differentially
abundant proteins
Synovial fluid samples from 57 JIA patients (Table 1) were
resolved on 2D gels to determine protein expression profiles. It
is apparent that several proteins formed a series of charge
trains (Fig. 1). This characteristic pattern of high-abundance
proteins is consistent with previous work by other laboratories
and our own [23,24]. Approximately 1300 spots per synovial
fluid gel image were detected and matched across patients.
Spot filtering on ‘master’ gels revealed 558 protein spots
which are differentially expressed in synovial fluid across
patient subgroups. Attention was focused on a series of 68
synovial fluid proteins (listed in Fig. 2) which displayed a
minimal 1.5-fold difference in pairwise comparisons be-
tween subgroups.
3.2. Discriminatory protein clustering, inter-subgroup
variation and protein identification
A heatmap was constructed with hierarchical cluster analysis
to visualize inter-individual expression patterns of the 68
filtered protein spots (Fig. 2). Euclidean ranked correlation
delineates seven distinctive clusters (A–G). Clusters C, F and G
comprise proteins consistently overexpressed (red) in both
oligoarticular and polyarticular patients relative to those
patients with disease extension, whereas protein levels in
clusters A, B and D are raised intermittently across all
subgroups. Cluster E contains proteins which are principally
amplified in polyarticular and extended-to-be oligoarticular
patients.
Fig. 1 – Fluorescence difference in-gel electrophoresis (DIGE) of synovial fluid. DIGE reveals 1300 spots per gel within the pH 4–7
range for synovial fluid (SF). Spot filtering on aggregate ‘master’ gels reveals 426 protein spots which are consistently
expressed in synovial fluid across patient subgroups. A series of 39 proteins that changed 50% or more in SF in later extended
oligoarticular compared to persistent oligoarticular patients are encircled and numbered above. The direction of the expression
change is indicated such that spots encircled green denote decreased proteins whereas red are increased relative to articular
patients. Spot numbers correlate to the clusters observed in the data after hierarchical cluster analysis, shown in Fig. 2. 68
proteins spots were cut from replicate preparative gels and 36 of these identified by MALDI-TOF analysis.
5485J O U R N A L O F P R O T E O M I C S 7 5 ( 2 0 1 2 ) 5 4 7 9 – 5 4 9 2Amongst the inter-subgroup differences which were sig-
nificant at the 5% level, protein spot 873 stands out (Table 2). It
resides within the distinctive cluster G of proteins that are
markedly suppressed in patients exhibiting disease exten-
sion. Spot 873, identified as an isoform of vitamin D binding
protein (VDBP) (see below), was decreased 8 fold and 4 fold in
extended-to‐be oligoarticular patients relative to persistent
oligoarticular and polyarticular patients, respectively. These
differences are significant (p=0.05 and p=0.03, respectively).
Two additional VDBP isoforms present as protein spots of
higher molecular mass (spots 1252 and 1253) showed about a 2
fold decrease in disease extended-to-be oligoarticular patients
(p=0.01).
Trypsin digestion and mass spectrometry (MS) followed by
MS/MS of spots 1252, 1253, 1431 and 1435 produced peptides
that aligned with the majority of VDBP amino acid sequence
(Supplementary Fig. 1). Since a number of differentially ex-
pressed VDBP spots were extracted from disparate sites on the
2DE gel, these proteins likely represent isoforms with subtle pI
or molecular weight differences due to post-translationalevents. However, digestion of spot 873 showed peptides that
aligned with a reduced portion of the parent protein sequence
between amino acids 218 and 420 (Fig. 3A). This data raises the
possibility of a low molecular weight (approx. 23 kDa), possibly
truncated isoform of VDBP distinct from the complete protein
(54.3 kDa).
Several other proteins including serum albumin (1375),
complement factor B (428), alpha-1-antitrypsin (228) and several
haptoglobin isoforms (750, 1265) were also substantially re-
duced in extended-to be oligoarticular patients. Conversely,
apolipoproteins A-I (1416) and A-II (905), and to a lesser extent
other haptoglobin isoforms (906, 1457), were increased in the
same subgroup of extended patients.
3.3. Verification of immunoreactive VDBP expression
Immunoprecipitation of synovial fluid samples and im-
munohistochemistry of synovial membranes from a rep-
resentative subset of patients were used to independently
validate the identification and expression patterns of VDBP.
5486 J O U R N A L O F P R O T E O M I C S 7 5 ( 2 0 1 2 ) 5 4 7 9 – 5 4 9 2Immunopurified and linearized VDBP band densities are
consistent with DIGE spot intensities of spots 873, 1252 and
1253 (Fig. 3B). A major band at approximately 52.9 kDa is
expressed heterogeneously within patient subgroups, but
nonetheless diminishedwithin the extended-to-be oligoarticular
subgroup.Fig. 2 – Heatmap analysis of synovial proteins differentially expre
in 68 preselected proteins over or under expressed 1.5 fold betw
protein expression data was reordered by hierarchical cluster an
revealing distinguishing expression patterns. The main clusters
represented by a single column, whereas each row represents a s
in oligoarticular patients who later become extended were ident
are shown in Fig. 1.Synovial membrane sections probed with the same VDBP
antibody displayed a disparate stain distribution character-
istic of perivascular expression at distinct sites within the
sublining layer of the tissue (Fig. 3C). Sialic acid glycosylation
motifs on synovial tissue proteins produced a similar
pattern.ssed across patient subgroups. The inter-individual variation
een patient subgroups is illustrated in heat map form. The
alysis (HCA) using Euclidean distance correlation (WPGMA),
of proteins are highlighted (A–G). Each patient sample is
ingle protein spot. The location of 36 proteins which changed
ified from preparative gel by MALDI-TOF mass spectrometry
Fig. 3 – Verification of protein expression and localization in synovial fluid and membrane. A. Representative MALDI-TOF mass spectra of spot 873 identified as vitamin
D-binding protein. Thematched peptide sequences are underlined within the sequence of vitamin D-binding protein. An approximatemolecular weight of the protein cleavage
product (between the arrows) is calculated from the amino acid sequence, in line with DIGE estimate. B. Immunoprecipitation of VDBP from synovial fluids of n=48
representative JIA patients (indicated by number in lanes 1–48; M—molecular weight marker; D— purified human VDBP positive control). Band densities of vitamin D binding
protein concur with protein expression levels measured by DIGE (extended-to-be oligoarticular patients in lanes 13, 21, 24, 36, 37, 45, 47, 48). C. Representative
immunohistochemistry of neighboring sections of synovial membrane from a polyarticular patient, all captured at 10× magnification. Vitamin D binding protein expression is
perivascular in nature. D. ELISA quantification of c-reactive protein and vitamin D binding protein concentration in initial plasma and synovial samples taken from the whole
study cohort. Error bars on the box-whisker plots represent range between maximum and minimum values; center line represents median. 5487
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5488 J O U R N A L O F P R O T E O M I C S 7 5 ( 2 0 1 2 ) 5 4 7 9 – 5 4 9 2A VDBP ELISA was used to measure immunoreactive VDBP
in each of the 57 individual JIA patient's plasma and synovial
fluid samples (Fig. 3D). Both immunoreactive VDBP and CRP
were higher in plasma than in synovial fluid. Immunoreactive
VDBP levels ranged from 42.0 to 277.0 ng/ml in plasma vs. 16.0
to 213.0 ng/ml in synovial fluid. CRP concentrations varied
over a wider interval: i.e., 78.0–115,149.0 ng/ml in plasma vs.
18.0–49,486.0 ng/ml in synovial fluid. VDBP and CRP wereFig. 4 –MALDI-TOFmass spectrometry of intact immunopurified V
A. MALDI-TOF mass spectrometry of immunoprecipitated and li
The peak intensity represented in as an individual ‘densitometry
of VDBP. The majority of intact forms of VDBP from plasma and s
the red dashed line). A peak shift towards the right resulting in a
isoforms of VDBP are also present in both fluids. B. MALDI-TOF m
neuraminidase digest from immunopurified VDBP from the syno
and 435.58m/z, representing release of sialic acid residues, are i
‘densitometry’ lanes. There is a significant 72.4 fold difference in
and extended-to-be oligoarticular patients, signifying few sialic a
patients (p=0.0014). C. Receiver operator characteristic curves to t
(red line) ELISA concentration values and DIGE derived normalize
m/z; blue line) released from VDBP to discern patients at risk of di
are also included in the accompanying table.markedly elevated in the plasma of both the extended-to-be
oligoarticular and polyarticular patient groups.
3.4. Verification of immunopurified VDBP isoform mass
variance and sialic acid modification
MALDI-TOF mass spectrometry of immunoprecipitated and
linearized VDBP from study patients reveals a major peakDBP and enzymatically released glycans diagnostic capacity.
nearized VDBP from a representative pool of study patients.
’ lane below the chart, reflects higher plasma concentrations
ynovial fluid have a peak mass of 52,900m/z (represented by
‘shoulder’ is apparent, indicating higher mass variants or
ass spectrometry of HILIC enriched glycan released by α2-3
vial fluid of oligoarticular patients. Glycan peaks at 237.65m/z
ndicated by the red encircled bands within individual patient
the normalized 237.65 m/z peak heights between persistent
cid modifications detected in the VDBP taken from the latter
est the sensitivity and specificity of VDBP (black line) and CRP
d volumes for spot 873 (green line) and sialic acid (peak 237.65
sease spread. Area under the curve and p values for each test
5489J O U R N A L O F P R O T E O M I C S 7 5 ( 2 0 1 2 ) 5 4 7 9 – 5 4 9 2with mass 52,900 m/z in line with estimates from the gel
electrophoresis and elevated plasma concentrations in
agreement with ELISA data (Fig. 4A). However, a peak shift
resulting in a ‘shoulder’ is apparent, indicating higher mass
variants or isoforms of VDBP are also present in both
fluids. Hydrophobic interaction liquid chromatography
(HILIC) enriched glycans, released by α2-3 neuraminidase
digest of immunopurified SF VDBP from oligoarticular
patients, were analyzed by MALDI-TOF mass spectrome-
try. Glycan peaks representing the release of sialic acid
residues from the peptide backbone of VDBP are evident
at 237.65 m/z and 435.58 m/z (Fig. 4B). The normalized
peak heights were significantly elevated in persistent
oligoarticular patients, signifying that fewer terminal sialic
acid modifications were present on VDBP from extended-to-be
patients. The 237.65 m/z peak height was 72.39 fold higher
(p=0.00019) and 435.58 m/z was 5.58 higher (p=0.00593) in
persistent oligo patients.
3.5. Assessment of VDBP isoforms as predictive tools
The diagnostic specificity and sensitivity of immunoreac-
tive VDBP and CRP (determined by ELISA) to predict
disease extension were compared to that of VDBP isoform
from spot 873 (using DIGE spot volumes) and the normal-
ized peak height of sialic acid (peak 237.65 m/z) enzymat-
ically released from immunopurified VDBP (Fig. 4C).
Receiver operator characteristic curves indicate that the
VDBP sialic acid motifs measured by MALDI-TOF give the
best specificity to identify at risk individuals (AUC 0.976;
p=0.00019). This compares favorably to VDBP (AUC=0.725),
spot 873 (AUC=0.692) and CRP (AUC=0.674). Sensitivity to
identify at risk patients is marginally improved with spot
873, relative to immunoreactive VDBP. Furthermore, the
discriminatory power of spot 873 was closer to significance
at p=0.099 than either immunoreactive VDBP (p=0.149) or
CRP (p=0.270).4. Discussion
Conventional measures of the acute phase response, includ-
ing CRP, were recorded within this study at similar levels
within in oligo and extended-to-be oligoarticular groups.
These markers do not aid in the clinical differentiation of
patients who will likely develop a range of adverse outcomes.
However, significantly higher levels (of CRP) were observed in
the polyarticular patients signifying the increased disease
activity experienced at an early stage by polyarticular
patients.
In contrast high resolution proteomic strategies can be
used to identify and quantify proteins and importantly
characterize the distinct modifications associated with a
particular disease subset. Recently, other groups have suc-
cessfully adopted a proteomic platform to identify biomarkers
which discern JIA subgroups building on our own preliminary
studies [6,9,25]. Rosenkranz et al. identified a subset of the
synovial proteome which could distinguish between oli-
goarticular, polyarticular and systemic forms of JIA. Hapto-
globin emerged as a particularly strong candidate biomarker.Ling et al. identified a panel of seven plasma proteins which
can discriminate patients at risk from an impending disease
flare with greater reliability than CRP or ESR. These results
suggest that for each clinical outcome/subtype a proteomic
profile exists and which has diagnostic or prognostic
potential.
This study documents a constellation of distinct vitamin
D binding proteins (VDBPs) with unique pI/MWt coordinates
produced in synovial fluid. Notably, in the extended-to-be
oligoarticular patient subgroup, a low molecular weight
species of VDBP is significantly reduced in the joint. This
may reflect increased degradation or represent a novel
post-translational truncation in at risk patients. Equally,
the elevated levels of immune-reactive VDBP, measured by
ELISA, in the plasma of extended-to-be oligoarticular
patients is a further indication of an altered expression
pattern. This data may seem incongruous until one con-
siders the technical differences of the analyses. Since the
ELISA assay relies on polyclonal capture and recognition of
VDBP it is unlikely to distinguish particular isoforms of the
complete protein. Low molecular weight isoforms may be
missing the antibody detected epitopes and therefore
‘overlooked’ by ELISA determination. Likewise the signifi-
cantly reduced glycosylation of SF VDBP from extended-
to-be oligoarticular patients would also go undetected by
ELISA. This illustrates the added benefit of using a proteo-
mic platform such as DIGE which can discern distinct
protein isoforms and highlights the importance of verifying
protein micro-heterogeneity across patient populations
when advancing biomarker candidates to clinical validation
[25].
VDBP (also known as Gc globulin) is an albumin-like
protein that requires cell surface binding to mediate some of
its functions [26]. Its reported biological roles include vitamin
D metabolite transport, fatty acid transport, actin sequestra-
tion, complement C5a chemotactic factor binding and inhibi-
tion of angiogenesis [27–30]. However, of special relevance to
the current study, VDBP has receivedmuch attention in recent
years as a precursor of the potent macrophage activation factor
Gc-MAFwhich can in turn release pro-inflammatory cytokines at
affected sites. Two of the best characterized forms of VDBP, Gc1s
and Gc1f, can have an O-linked trisaccharide coupled to a
threonine residue at position 420 (T420) in the amino acid
sequence. To date, 120 variant isoforms have been reported
[30–32]. Studies suggest that when VDBP is subjected to sequen-
tial B cell β-galactosidase and T cell sialidase treatment, this
generates GcMAF by converting the trisaccharide at T420 to a
single sialic acid residue (GalNAc) [32–34]. Substitution for a lysine
at this position in an alternate form Gc2 prevents this isoform
from being glycosylated at this position. In addition to the
subtype related levels of VDBP noted in this study cohort, it is
compelling to suggest that the differential modification of the
protein observed may also be important in the pathology of JIA.
Studies of biologic drug efficacy in the rheumatic disorders RA
and JIA report increased levels of systemic VDBP and apolipopro-
tein A-I in successful responders, suggesting a shift toward
‘normal’macrophageactivation levels [35,36]. Furthermore, VDBP
has been isolated frommultiple sclerosis patients suffering from
a relapsing remitting form of the disease, where it is thought to
play a role in T cell activation and differentiation [37]. On
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isoforms could have a disrupted macrophage activation system
at the joint levelwhich increases the chances of disease spread to
distant joints by an unknown pathway. The reduced levels of
sialic acid residues observed in the VDBP of extended-to-be
oligoarticular patients adds further weight to this hypothesis.
Similarly, reduced levels of fucosylated epitopes on an
unidentified 26 kDa protein have been recorded in JIA and RA
patients [18].
Independent studies suggest that alongwith VDBP isoforms,
haptoglobin and apolipoprotein A‐II could form a composite
biomarker test with greater predictive strength [6,9]. In this
study extended-to-be oligoarticular patients display a general
trend toward reductions in select isoforms of haptoglobin,
alpha-1-antitrypsin and complement factor B relative to the
other two patient subgroups. Haptoglobin has been shown to be
involved in angiogenesis, tissue remodeling and cell migration
[38], whereas complement activation in synovial fluid may
influence phagocyte migration during joint inflammation
[39,40]. Thus these host-response proteins could be involved
in the spread of inflammation to previously unaffected joints.
The significant drop in the levels of truncated and
glycosylated isoforms of VDBP is intriguing and suggests an
altered synovial turnover of complete ‘parent’ VDBP in JIA
patients at risk of disease extension. Thesemodifications likely
have a dramatic effect on the protein's function andmay play a
significant role in the pathology of early disease in JIA.
Accordingly, changing levels of protein modification may
represent a better biomarker than changes in the protein's
expression levels alone. Indeed, the sensitivity and specificity
observed likely stems from the combined measures of protein
and glycosylation levels. The reliability of outcome prediction
will evidently require further validation in independent cohorts
and such a technically intricate assay would need to be
converted to amore clinically robust and user friendly platform.
Weenvision that amultiplexed protein test capable of resolving
disease specific modifications could assist in predicting the
disease evolution, enabling earlier appropriate intervention,
and thus reducing pain, disability and joint damage.Abbreviations
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